Targeted therapies for hepatocellular carcinoma

Area of Science:

• Hepatobiliary oncology
• Molecular targeted therapy
• Cancer genomics

Background:

• Hepatocellular carcinoma (HCC) incidence and mortality are rising in the US and Europe, with most patients diagnosed at advanced stages.
• Current systemic therapies for HCC, like sorafenib (a tyrosine kinase inhibitor), show efficacy but face challenges due to tumor genetic heterogeneity.
• Understanding the molecular pathogenesis and identifying specific oncogene addictions are crucial for developing effective HCC treatments.

Purpose of the Study:

• To review the current landscape of systemic therapies for hepatocellular carcinoma (HCC).
• To highlight the need for improved understanding of HCC molecular pathogenesis to guide personalized treatment strategies.
• To discuss ongoing and future clinical trials evaluating tyrosine kinase inhibitors (TKIs) and combination therapies for advanced HCC.

Main Methods:

• Review of current clinical trials and literature on systemic therapies for HCC.
• Analysis of the role of genetic heterogeneity and oncogene addiction in cancer treatment response.
• Exploration of emerging therapeutic strategies, including TKIs and combination regimens.

Main Results:

• Numerous clinical trials are evaluating TKIs, both as monotherapy and in combination, for first- and second-line HCC treatment.
• Identification of specific oncogenes driving HCC progression could lead to targeted therapies and personalized treatment approaches.
• Combination therapies and novel reagents targeting signaling pathways show promise for managing advanced HCC.

Conclusions:

• Advancements in understanding HCC molecular pathogenesis are essential for developing more effective and personalized systemic therapies.
• Ongoing trials with various tyrosine kinase inhibitors and combination strategies may significantly alter the management of advanced HCC.
• Biomarker identification and targeted interventions hold the potential to improve treatment efficacy and cost-effectiveness for selected HCC patient populations.